董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Tracy M. Woody | 女 | Independent Director | 55 | 51.34万美元 | 未持股 | 2025-11-17 |
| Craig Thompson | 男 | Director | 58 | 未披露 | 未持股 | 2025-11-17 |
| Sheldon L. Koenig | -- | Director, President and Chief Executive Officer | -- | 未披露 | 未持股 | 2025-11-17 |
| J. Martin Carroll | -- | Chairman of the Board | -- | 未披露 | 未持股 | 2025-11-17 |
| Robert E. Hoffman | -- | Independent Director | -- | 未披露 | 未持股 | 2025-11-17 |
| Stephen C. Rocamboli | -- | Independent Director | -- | 未披露 | 未持股 | 2025-11-17 |
| Seth H.Z. Fischer | -- | Independent Director | -- | 未披露 | 未持股 | 2025-11-17 |
| Jay P. Shepard | 男 | Independent Director | 67 | 30.84万美元 | 未持股 | 2025-11-17 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sheldon L. Koenig | -- | Director, President and Chief Executive Officer | -- | 未披露 | 未持股 | 2025-11-17 |
| Benjamin Halladay | -- | Chief Financial Officer and Principal Accounting Officer | -- | 未披露 | 未持股 | 2025-11-17 |
| Benjamin O. Looker | -- | General Counsel | -- | 未披露 | 未持股 | 2025-11-17 |
| John B. Harlow, Jr. | 男 | Chief Commercial Officer | -- | 未披露 | 未持股 | 2025-11-17 |
董事简历
中英对照 | 中文 | 英文- Tracy M. Woody
-
Tracy M. Woody，自2015年2月以来，她一直担任首席商务官。她曾创立并担任TMW Consulting公司（咨询公司，与新兴生物技术和医疗设备公司合作）的董事总经理（从2013年到2015年2月）。作为她的顾问工作的一部分，她曾担任RetroJect公司（一个私人眼科医疗设备公司）的代理首席执行官（从2013年到2015年2月）。她曾担任NextWave Pharmaceuticals的副总裁，负责销售和营销（从2010年到2012年12月）。她曾担任The Greer Labs公司（过敏免疫疗法公司）的业务开发副总裁、销售和营销副总裁（从2002年到2010年）。从1999年到2001年，她曾担任ALZA Corporation（研究制药公司）的营销董事。她持有East Carolina大学的学士学位。
Tracy M. Woody has served as a member of board since May 2019. Ms. Woody currently leads TMW Consulting where she works with both early-stage companies to provide initial commercial input, and companies in Phase 3 to develop and guide successful launch plans. Ms. Woody previously served as Chief Commercial Officer of Versartis, Inc. from 2017 to 2018 and KemPharm, Inc. from 2015 to 2016. Prior to KemPharm, Ms. Woody was Vice President of Sales and Marketing of NextWave Pharmaceuticals acquired by Pfizer, and Vice President of Business Development and Vice President of Sales and Marketing at Greer Laboratories. Ms. Woody has over 20 years of commercial experience in pharmaceuticals, biologics, and medical devices, across a wide range of therapeutic areas in diverse markets. Ms. Woody also has experience with multi-billion dollar revenue brands as well as products in the rare disease space. Ms. Woody holds a Bachelor's degree in Health Promotion and Applied Physiology from East Carolina University. - Tracy M. Woody，自2015年2月以来，她一直担任首席商务官。她曾创立并担任TMW Consulting公司（咨询公司，与新兴生物技术和医疗设备公司合作）的董事总经理（从2013年到2015年2月）。作为她的顾问工作的一部分，她曾担任RetroJect公司（一个私人眼科医疗设备公司）的代理首席执行官（从2013年到2015年2月）。她曾担任NextWave Pharmaceuticals的副总裁，负责销售和营销（从2010年到2012年12月）。她曾担任The Greer Labs公司（过敏免疫疗法公司）的业务开发副总裁、销售和营销副总裁（从2002年到2010年）。从1999年到2001年，她曾担任ALZA Corporation（研究制药公司）的营销董事。她持有East Carolina大学的学士学位。
- Tracy M. Woody has served as a member of board since May 2019. Ms. Woody currently leads TMW Consulting where she works with both early-stage companies to provide initial commercial input, and companies in Phase 3 to develop and guide successful launch plans. Ms. Woody previously served as Chief Commercial Officer of Versartis, Inc. from 2017 to 2018 and KemPharm, Inc. from 2015 to 2016. Prior to KemPharm, Ms. Woody was Vice President of Sales and Marketing of NextWave Pharmaceuticals acquired by Pfizer, and Vice President of Business Development and Vice President of Sales and Marketing at Greer Laboratories. Ms. Woody has over 20 years of commercial experience in pharmaceuticals, biologics, and medical devices, across a wide range of therapeutic areas in diverse markets. Ms. Woody also has experience with multi-billion dollar revenue brands as well as products in the rare disease space. Ms. Woody holds a Bachelor's degree in Health Promotion and Applied Physiology from East Carolina University.
- Craig Thompson
-
Craig Thompson自2016年1月7日起担任公司总裁兼首席运营官。之前，2014年2月至2015年12月Thompson先生担任Tetraphase Pharmaceuticals的首席营运官，在那里他负责商业战略、企业发展和商业化生产的制定和实施。在Tetraphase Pharmaceuticals之前，2011年1月至2014年12月，Thompson先生担任Tetraphase Pharmaceuticals的首席商务官，在这段时间，Trius被Cubist Pharmaceuticals公司以超过7亿美元收购。在Trius治疗之前，2003年11月至2010年12月Thompson先生在Pfizer担任越来越重要的不同职务，最后一个职务是Specialty Care的副总裁。Thompson先生持有McMaster大学的商业学士学位和Notre Dame大学的工商管理硕士学位。
Craig Thompson has served as a member of Board of Directors since December 2016. Mr. Thompson was appointed to serve as the Company's President effective January 7 2016 and to serve on the board of directors and as the Company's Chief Executive Officer effective December 6 2016. Most recently he served as the Chief Operating Officer for Tetraphase Pharmaceuticals from February 2014 to December 2015 where he oversaw the development and implementation of the commercial strategy as well as the business development and commercial manufacturing. Prior to Tetraphase Pharmaceuticals, from January 2011 to December 2014 Mr. Thompson served as the Chief Commercial Officer for Trius Therapeutics resulting in the acquisition of Trius by Cubist Pharmaceuticals for over $700 million. Prior to Trius Therapeutics, Mr. Thompson held various positions of increasing responsibility with Pfizer from November 2003 to December 2010 with his last position as Vice President of Marketing, Specialty Care. Prior to Pfizer he held various positions of increasing responsibility at Merck and Co, Inc. from April 1993 to November 2003. Mr. Thompson holds a Bachelor's degree in Commerce from McMaster University and a Master's degree in Business Administration from the University of Notre Dame. - Craig Thompson自2016年1月7日起担任公司总裁兼首席运营官。之前，2014年2月至2015年12月Thompson先生担任Tetraphase Pharmaceuticals的首席营运官，在那里他负责商业战略、企业发展和商业化生产的制定和实施。在Tetraphase Pharmaceuticals之前，2011年1月至2014年12月，Thompson先生担任Tetraphase Pharmaceuticals的首席商务官，在这段时间，Trius被Cubist Pharmaceuticals公司以超过7亿美元收购。在Trius治疗之前，2003年11月至2010年12月Thompson先生在Pfizer担任越来越重要的不同职务，最后一个职务是Specialty Care的副总裁。Thompson先生持有McMaster大学的商业学士学位和Notre Dame大学的工商管理硕士学位。
- Craig Thompson has served as a member of Board of Directors since December 2016. Mr. Thompson was appointed to serve as the Company's President effective January 7 2016 and to serve on the board of directors and as the Company's Chief Executive Officer effective December 6 2016. Most recently he served as the Chief Operating Officer for Tetraphase Pharmaceuticals from February 2014 to December 2015 where he oversaw the development and implementation of the commercial strategy as well as the business development and commercial manufacturing. Prior to Tetraphase Pharmaceuticals, from January 2011 to December 2014 Mr. Thompson served as the Chief Commercial Officer for Trius Therapeutics resulting in the acquisition of Trius by Cubist Pharmaceuticals for over $700 million. Prior to Trius Therapeutics, Mr. Thompson held various positions of increasing responsibility with Pfizer from November 2003 to December 2010 with his last position as Vice President of Marketing, Specialty Care. Prior to Pfizer he held various positions of increasing responsibility at Merck and Co, Inc. from April 1993 to November 2003. Mr. Thompson holds a Bachelor's degree in Commerce from McMaster University and a Master's degree in Business Administration from the University of Notre Dame.
- Sheldon L. Koenig
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- J. Martin Carroll
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Robert E. Hoffman
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Stephen C. Rocamboli
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Seth H.Z. Fischer
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Jay P. Shepard
-
Jay P. Shepard，2015年至2020年1月担任Aravive, Inc.（前身为Versartis，Inc.）总裁兼首席执行官，自2013年起担任其董事会成员，自2020年1月起担任其董事长。从2012年到2015年，Shepard先生是Sofinnova Ventures的执行合伙人，这是一家专注于医疗保健行业的风险投资公司，他于2008年作为高管加入Residence。2010年至2012年，Shepard先生担任总裁兼首席执行官，并且是NextWave Pharmaceuticals，Inc.的董事会成员，该公司是一家利用专有给药技术开发和商业化独特儿科产品的专业制药公司，该公司已被辉瑞公司收购。2005年至2007年，Shepard先生担任Ilypsa，Inc.的总裁兼首席执行官和董事会成员，一家率先开发用于肾脏和代谢紊乱的新型非吸收聚合物药物的生物制药公司，已被安进公司收购。Shepard先生目前在Esperion Therapeutics，Inc.和Ironwood医药的董事会任职，并担任Christopher & 达纳 Reeve基金会的主席。Shepard先生拥有亚利桑那大学工商管理学士学位。
Jay P. Shepard,was President and Chief Executive Officer of Aravive, Inc. (formerly Versartis, Inc.) from 2015 to January 2020 and has served as a member of its board of directors since 2013 and as its Chairman since January 2020. From 2012 until 2015, Mr. Shepard was an Executive Partner at Sofinnova Ventures, a venture capital firm focused on the healthcare industry, which he joined as an Executive in Residence in 2008. From 2010 to 2012, Mr. Shepard served as President and Chief Executive Officer and was a member of the board of directors of NextWave Pharmaceuticals, Inc., a specialty pharmaceutical company developing and commercializing unique pediatric products utilizing proprietary drug delivery technology that was acquired by Pfizer, Inc. From 2005 to 2007, Mr. Shepard served as President and Chief Executive Officer and a member of the board of directors of Ilypsa, Inc., a biopharmaceutical company pioneering novel non-absorbed polymeric drugs for renal and metabolic disorders that was acquired by Amgen Inc. Mr. Shepard currently serves on the board of directors of Esperion Therapeutics, Inc. and Ironwood Pharmaceuticals, and serves as the Chairman of the Christopher & Dana Reeve Foundation. Mr. Shepard holds a B.S. in Business Administration from the University of Arizona. - Jay P. Shepard，2015年至2020年1月担任Aravive, Inc.（前身为Versartis，Inc.）总裁兼首席执行官，自2013年起担任其董事会成员，自2020年1月起担任其董事长。从2012年到2015年，Shepard先生是Sofinnova Ventures的执行合伙人，这是一家专注于医疗保健行业的风险投资公司，他于2008年作为高管加入Residence。2010年至2012年，Shepard先生担任总裁兼首席执行官，并且是NextWave Pharmaceuticals，Inc.的董事会成员，该公司是一家利用专有给药技术开发和商业化独特儿科产品的专业制药公司，该公司已被辉瑞公司收购。2005年至2007年，Shepard先生担任Ilypsa，Inc.的总裁兼首席执行官和董事会成员，一家率先开发用于肾脏和代谢紊乱的新型非吸收聚合物药物的生物制药公司，已被安进公司收购。Shepard先生目前在Esperion Therapeutics，Inc.和Ironwood医药的董事会任职，并担任Christopher & 达纳 Reeve基金会的主席。Shepard先生拥有亚利桑那大学工商管理学士学位。
- Jay P. Shepard,was President and Chief Executive Officer of Aravive, Inc. (formerly Versartis, Inc.) from 2015 to January 2020 and has served as a member of its board of directors since 2013 and as its Chairman since January 2020. From 2012 until 2015, Mr. Shepard was an Executive Partner at Sofinnova Ventures, a venture capital firm focused on the healthcare industry, which he joined as an Executive in Residence in 2008. From 2010 to 2012, Mr. Shepard served as President and Chief Executive Officer and was a member of the board of directors of NextWave Pharmaceuticals, Inc., a specialty pharmaceutical company developing and commercializing unique pediatric products utilizing proprietary drug delivery technology that was acquired by Pfizer, Inc. From 2005 to 2007, Mr. Shepard served as President and Chief Executive Officer and a member of the board of directors of Ilypsa, Inc., a biopharmaceutical company pioneering novel non-absorbed polymeric drugs for renal and metabolic disorders that was acquired by Amgen Inc. Mr. Shepard currently serves on the board of directors of Esperion Therapeutics, Inc. and Ironwood Pharmaceuticals, and serves as the Chairman of the Christopher & Dana Reeve Foundation. Mr. Shepard holds a B.S. in Business Administration from the University of Arizona.
高管简历
中英对照 | 中文 | 英文- Sheldon L. Koenig
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Benjamin Halladay
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Benjamin O. Looker
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- John B. Harlow, Jr.
John B. Harlow，Jr.担任Melinta Therapeutics的首席商务官，该公司是一家商业阶段的公司，专注于治疗急性和危及生命的疾病的创新疗法。从2019年11月到2021年3月，Harlow先生在Baudax Bio担任首席商务官，该公司是一家商业阶段的公司，专注于急性护理环境的治疗。2016年10月至2019年11月，Harlow先生在Recro Pharma担任执行副总裁兼商业和营销副总裁职务。在其职业生涯的早期，哈洛曾在Endo、Shionogi、辉瑞和诺华担任越来越重要的职务。Harlow先生拥有Lehigh大学生物学学士学位和Seton Hall大学工商管理硕士学位。
John B. Harlow, Jr.,served as the Chief Commercial Officer of Melinta Therapeutics, a commercial stage company focused on innovative therapies for acute and life-threatening illnesses. From November 2019 to March 2021, Mr. Harlow was Chief Commercial Officer at Baudax Bio, a commercial stage company focused on therapeutics for acute care settings. From October 2016 to November 2019, Mr. Harlow held Executive Vice President and Vice President roles in commercial and marketing at Recro Pharma. Earlier in his career, Mr. Harlow held roles of increasing responsibility at Endo, Shionogi, Pfizer, and Novartis. Mr. Harlow holds a Bachelor of Science in biology from Lehigh University and a Master of Business Administration from Seton Hall University.- John B. Harlow，Jr.担任Melinta Therapeutics的首席商务官，该公司是一家商业阶段的公司，专注于治疗急性和危及生命的疾病的创新疗法。从2019年11月到2021年3月，Harlow先生在Baudax Bio担任首席商务官，该公司是一家商业阶段的公司，专注于急性护理环境的治疗。2016年10月至2019年11月，Harlow先生在Recro Pharma担任执行副总裁兼商业和营销副总裁职务。在其职业生涯的早期，哈洛曾在Endo、Shionogi、辉瑞和诺华担任越来越重要的职务。Harlow先生拥有Lehigh大学生物学学士学位和Seton Hall大学工商管理硕士学位。
- John B. Harlow, Jr.,served as the Chief Commercial Officer of Melinta Therapeutics, a commercial stage company focused on innovative therapies for acute and life-threatening illnesses. From November 2019 to March 2021, Mr. Harlow was Chief Commercial Officer at Baudax Bio, a commercial stage company focused on therapeutics for acute care settings. From October 2016 to November 2019, Mr. Harlow held Executive Vice President and Vice President roles in commercial and marketing at Recro Pharma. Earlier in his career, Mr. Harlow held roles of increasing responsibility at Endo, Shionogi, Pfizer, and Novartis. Mr. Harlow holds a Bachelor of Science in biology from Lehigh University and a Master of Business Administration from Seton Hall University.